Journal article
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
J Grebely, O Dalgard, EB Cunningham, B Hajarizadeh, GR Foster, P Bruggmann, B Conway, M Backmund, G Robaeys, T Swan, J Amin, PS Marks, S Quiene, TL Applegate, M Weltman, D Shaw, A Dunlop, M Hellard, J Bruneau, H Midgard Show all
International Journal of Drug Policy | ELSEVIER SCIENCE BV | Published : 2017
Abstract
Background There are few data on treatment for hepatitis C virus (HCV) infection among people with ongoing injecting drug use. This study evaluated the efficacy of response-guided therapy for chronic HCV genotypes 2/3 infection among people with ongoing injecting drug use or receiving opioid substitution therapy (OST). A secondary aim was to identify predictors of HCV treatment response. Methods ACTIVATE was a multicentre clinical trial recruited between 2012 and 2014. Participants with genotypes 2/3 were treated with directly observed peg-interferon alfa-2b and self-administered ribavirin for 12 (undetectable HCV RNA at week 4) or 24 weeks (detectable HCV RNA at week 4). Participants were r..
View full abstractGrants
Funding Acknowledgements
Supported in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp. The Kirby Institute is funded by the Australian Government Department of Health. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. BH is supported by a National Health and Medical Research Council Early Career Fellowship. MH is supported by a National Health and Medical Research Council Principal Research Fellowship. GD is supported by a National Health and Medical Research Council Practitioner Research Fellowships.